

16 Jan 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 January 2022, including: easy alliances rather than big deals the focus at J.P. Morgan; other roundups from the JPM meeting; and [Eli Lilly and Company](#) braces for impact of CMS decision on Aduhelm.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Deals Or No Deals, J.P. Morgan Sets The Tone For 2022](#)" - Scrip, 12 Jan, 2022.)

(Also see "[Amgen CEO Bradway On Deals: Good \(Smaller\) Opportunities Are Vast](#)" - Scrip, 11 Jan, 2022.)

(Also see "[J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals](#)" - Scrip, 10 Jan, 2022.)

(Also see "[J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron](#)" - Scrip, 11 Jan, 2022.)

(Also see "[Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen's Aduhelm](#)" - Scrip, 11

Jan, 2022.)

[Click here to explore this interactive content online](#) ✨